{"id":8751,"date":"2023-10-11T18:15:06","date_gmt":"2023-10-11T15:15:06","guid":{"rendered":"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/"},"modified":"2023-10-11T18:15:06","modified_gmt":"2023-10-11T15:15:06","slug":"prevention-du-vrs-chez-les-nouveau-nes","status":"publish","type":"post","link":"https:\/\/urbancare.clinic\/fr\/prevention-du-vrs-chez-les-nouveau-nes\/","title":{"rendered":"Pr\u00e9vention du VRS chez les nouveau-n\u00e9s"},"content":{"rendered":"
<\/div>\n

Beyfortus (nom g\u00e9n\u00e9rique : Nirsevimab) a \u00e9t\u00e9 approuv\u00e9 par la Food and Drug Administration (FDA) des \u00c9tats-Unis le 17 juillet 2023. Beyfortus est un anticorps monoclonal \u00e0 action prolong\u00e9e con\u00e7u pour prot\u00e9ger les nouveau-n\u00e9s et les nourrissons contre une infection par le virus respiratoire syncytial (VRS) sous surveillance m\u00e9dicale. . Aux fins des essais cliniques du m\u00e9dicament Beyfortus, le terme \u00ab suivi m\u00e9dical \u00bb fait r\u00e9f\u00e9rence \u00e0 toute infection \u00e0 RSV n\u00e9cessitant une visite m\u00e9dicale au cabinet, aux soins d'urgence ou \u00e0 l'h\u00f4pital.
Le VRS est la cause la plus fr\u00e9quente d\u2019infections pulmonaires inf\u00e9rieures chez les enfants de moins d\u2019un an. Ces types d\u2019infections pulmonaires comprennent la bronchiolite et\/ou la pneumonie. La bronchiolite commence souvent par un \u00e9coulement nasal et une toux, mais peut s'aggraver pour inclure une respiration plus rapide, une respiration sifflante, des cr\u00e9pitements et la n\u00e9cessit\u00e9 de travailler plus fort pour respirer. Les nourrissons risquent de d\u00e9velopper une apn\u00e9e, d\u00e9finie comme une pause temporaire de la respiration ou une absence de respiration pendant plus de 20 secondes.<\/p>\n

Selon les Centers for Disease Control and Prevention (CDC), le RSV provoque chaque ann\u00e9e environ 2,1 millions de visites chez le m\u00e9decin hors h\u00f4pital chez les enfants de moins de 5 ans.1<\/sup> ainsi que 58 000 \u00e0 80 000 hospitalisations chaque ann\u00e9e dans cette m\u00eame tranche d\u2019\u00e2ge. (1,2,3<\/sup>) Ils signalent chaque ann\u00e9e 100 \u00e0 300 d\u00e9c\u00e8s d\u2019enfants de moins de 5 ans dus au VRS.4<\/sup>
Les nouveau-n\u00e9s et les nourrissons de moins de six mois et ceux n\u00e9s pr\u00e9matur\u00e9ment (avant 35 semaines de gestation) courent le plus grand risque de d\u00e9velopper une infection suffisamment grave pour n\u00e9cessiter une hospitalisation. Ces infections par le VRS n\u00e9cessitent g\u00e9n\u00e9ralement une surveillance \u00e9troite de la respiration du jeune enfant. Le nourrisson ou l'enfant hospitalis\u00e9 peut avoir besoin d'une assistance respiratoire, de m\u00e9dicaments et d'un apport liquidien intraveineux (IV) pendant la pire partie de la maladie.<\/p>\n

Beyfortus a \u00e9t\u00e9 cr\u00e9\u00e9 pour pr\u00e9venir une infection grave par le VRS chez les nourrissons au cours de leur premi\u00e8re saison du VRS, lorsqu'ils sont les plus \u00e0 risque de complications du virus. Selon un communiqu\u00e9 de presse du fabricant Sanofi : \u00ab L'administration unique de Beyfortus a \u00e9t\u00e9 d\u00e9velopp\u00e9e pour correspondre au d\u00e9but de la saison du VRS pour les b\u00e9b\u00e9s n\u00e9s avant la saison ou \u00e0 la naissance pour ceux n\u00e9s pendant la saison du VRS. Dans le cadre d'essais cliniques, Beyfortus a contribu\u00e9 \u00e0 pr\u00e9venir la maladie des voies respiratoires inf\u00e9rieures due au VRS n\u00e9cessitant des soins m\u00e9dicaux dans toutes les populations de nourrissons \u00e9tudi\u00e9es, y compris ceux n\u00e9s \u00e0 terme, peu pr\u00e9matur\u00e9s ou pr\u00e9matur\u00e9s en bonne sant\u00e9, ou pr\u00e9sentant des probl\u00e8mes de sant\u00e9 sp\u00e9cifiques qui les rendent vuln\u00e9rables \u00e0 une maladie grave \u00e0 VRS. Les maladies \u00e0 VRS n\u00e9cessitant des soins m\u00e9dicaux comprenaient le cabinet d\u2019un m\u00e9decin, les soins d\u2019urgence, les visites aux urgences et les hospitalisations.5<\/sup><\/p>\n

Le Comit\u00e9 consultatif sur les pratiques d'immunisation (ACIP) et l'American Academy of Pediatrics (AAP) recommandent d\u00e9sormais Beyfortus \u00e0 tous les nourrissons de moins de 8 mois pendant ou entrant dans leur premi\u00e8re saison de VRS. Le gouvernement f\u00e9d\u00e9ral est intervenu pour couvrir le co\u00fbt des m\u00e9dicaments en milieu extra-hospitalier pour les enfants inscrits au programme de vaccins pour enfants (VFC). Le programme VFC aide g\u00e9n\u00e9ralement \u00e0 fournir des vaccins aux enfants dont les tuteurs n'auraient peut-\u00eatre pas pu se les procurer autrement. Les assureurs priv\u00e9s n\u2019ont pas d\u00e9termin\u00e9 quelle part du pr\u00e9tendu co\u00fbt du $415 ils envisagent de couvrir.<\/p>\n

Cela laisse aux h\u00f4pitaux et aux cabinets m\u00e9dicaux priv\u00e9s le soin de d\u00e9terminer la meilleure fa\u00e7on de d\u00e9ployer ce m\u00e9dicament, ce qui suscite des inqui\u00e9tudes quant \u00e0 l\u2019acc\u00e8s et \u00e0 l\u2019\u00e9quit\u00e9. Les prestataires proposant le Beyfortus couvert par VFC dans leurs cabinets doivent \u00e9galement le proposer aux patients b\u00e9n\u00e9ficiant d'une assurance priv\u00e9e. Cela signifie payer entre des milliers et un million de dollars pour offrir ce m\u00e9dicament. Un co\u00fbt qui pourrait ne pas \u00eatre r\u00e9cup\u00e9r\u00e9 par la plupart des h\u00f4pitaux ou cabinets. Les d\u00e9cisions seront alors probablement prises au niveau local d'offrir ou non Beyfortus \u00e0 un enfant, ce qui rendra la distribution au mieux variable et au pire exclure ceux des zones les moins riches.<\/p>\n

Beyfortus r\u00e9duit le risque d'infection par le VRS n\u00e9cessitant des soins m\u00e9dicaux d'environ 70-75% par rapport au placebo.6<\/sup> Malgr\u00e9 ces donn\u00e9es, l\u2019analyse co\u00fbts-avantages doit \u00eatre prise au s\u00e9rieux. Pour tout parent ayant un enfant malade ou hospitalis\u00e9 atteint du VRS, il n\u2019y a aucun co\u00fbt trop \u00e9lev\u00e9 pour pr\u00e9venir cette maladie. Les h\u00f4pitaux du pays sont confront\u00e9s \u00e0 de graves contraintes financi\u00e8res, avec un acc\u00e8s aux soins consid\u00e9rablement restreint, en particulier dans les zones rurales. Plus t\u00f4t cette ann\u00e9e, un rapport du Center for Healthcare Quality and Payment Reform a soulign\u00e9 le risque de voir de nouveaux h\u00f4pitaux fermer dans un avenir proche : \u00ab Plus de 100 h\u00f4pitaux ruraux ont ferm\u00e9 leurs portes au cours de la derni\u00e8re d\u00e9cennie, et plus de 600 h\u00f4pitaux ruraux suppl\u00e9mentaires \u2014 plus de 30% de tous les h\u00f4pitaux ruraux du pays risquent de fermer dans un avenir proche. Les h\u00f4pitaux ruraux risquent de fermer parce qu\u2019ils perdent de l\u2019argent en fournissant des services aux patients. Dans le pass\u00e9, de nombreux h\u00f4pitaux ont re\u00e7u des subventions, des recettes fiscales locales ou des subventions d\u2019autres entreprises pour compenser ces pertes, mais rien ne garantit que ces fonds continueront d\u2019\u00eatre disponibles ou seront suffisants pour couvrir les co\u00fbts plus \u00e9lev\u00e9s auxquels les h\u00f4pitaux sont confront\u00e9s. Des millions de personnes pourraient \u00eatre directement touch\u00e9es si ces h\u00f4pitaux fermaient. \u00bb7<\/sup><\/p>\n

Alors que les assureurs, le gouvernement et les prestataires m\u00e9dicaux prennent en compte ces facteurs complexes, la saison du VRS approche \u00e0 grands pas. Il est fort probable que la mise en \u0153uvre compl\u00e8te et la disponibilit\u00e9 de Beyfortus ne seront pas appr\u00e9ci\u00e9es au cours de la prochaine saison du RSV.<\/p>\n

Ouvrages cit\u00e9s:<\/p>\n

    \n
  1. Hall CB, Weinberg GA, Iwane MK et al. Le fardeau de l\u2019infection par le virus respiratoire syncytial chez les jeunes enfants. Nouvel Anglais J Med. 2009;360(6):588-98.<\/a><\/li>\n
  2. Rha B, Curns AT, Lively JY et al. Hospitalisations associ\u00e9es au virus respiratoire syncytial chez les jeunes enfants\u00a0: 2015-2016. P\u00e9diatrie. 2020;146(1):e20193611.<\/a><\/li>\n
  3. McLaughlin JM, Khan F, Schmitt HJ et coll. Taux d'hospitalisation associ\u00e9s au virus respiratoire syncytial chez les nourrissons am\u00e9ricains\u00a0: une revue syst\u00e9matique et une m\u00e9ta-analyse. JID. 2022;225(6):1100-1111.<\/a><\/li>\n
  4. Hansen CL, Chaves SS, Demont C, Viboud C. Mortalit\u00e9 associ\u00e9e \u00e0 la grippe et au virus respiratoire syncytial aux \u00c9tats-Unis, 1999-2018.R\u00e9seau JAMA ouvert. 1er f\u00e9vrier 2022;5(2):e220527.<\/a><\/li>\n
  5. https:\/\/www.news.sanofi.us\/2023-07-17-FDA-approves-Beyfortus-TM-nirsevimab-alip-to-protect-infants-against-RSV-disease<\/a><\/li>\n
  6. https:\/\/www.beyfortus.com\/hcp\/efficacy-and-safety#Efficacy<\/a><\/li>\n
  7. Sauver les h\u00f4pitaux ruraux \u2013 La crise des soins de sant\u00e9 en milieu rural (chqpr.org)<\/a><\/li>\n<\/ol>\n

    Source quotidienne m\u00e9dicale<\/a><\/p>\n

    ","protected":false},"excerpt":{"rendered":"

    <\/div>\n

    Beyfortus (nom g\u00e9n\u00e9rique : Nirsevimab) a \u00e9t\u00e9 approuv\u00e9 par la Food and Drug Administration (FDA) des \u00c9tats-Unis le 17 juillet 2023. Beyfortus est un anticorps monoclonal \u00e0 action prolong\u00e9e con\u00e7u pour prot\u00e9ger les nouveau-n\u00e9s et les nourrissons contre une infection par le virus respiratoire syncytial (VRS) sous surveillance m\u00e9dicale. . Aux fins des essais cliniques du m\u00e9dicament Beyfortus, le terme \u00ab suivi m\u00e9dical \u00bb fait r\u00e9f\u00e9rence \u00e0 toute infection \u00e0 RSV n\u00e9cessitant une visite m\u00e9dicale au cabinet, aux soins d'urgence ou \u00e0 l'h\u00f4pital.
    Le VRS est la cause la plus fr\u00e9quente d\u2019infections pulmonaires inf\u00e9rieures chez les enfants de moins d\u2019un an. Ces types d\u2019infections pulmonaires comprennent la bronchiolite et\/ou la pneumonie. La bronchiolite commence souvent par un \u00e9coulement nasal et une toux, mais peut s'aggraver pour inclure une respiration plus rapide, une respiration sifflante, des cr\u00e9pitements et la n\u00e9cessit\u00e9 de travailler plus fort pour respirer. Les nourrissons risquent de d\u00e9velopper une apn\u00e9e, d\u00e9finie comme une pause temporaire de la respiration ou une absence de respiration pendant plus de 20 secondes.<\/p>\n

    Selon les Centers for Disease Control and Prevention (CDC), le RSV provoque chaque ann\u00e9e environ 2,1 millions de visites chez le m\u00e9decin hors h\u00f4pital chez les enfants de moins de 5 ans.1<\/sup> ainsi que 58 000 \u00e0 80 000 hospitalisations chaque ann\u00e9e dans cette m\u00eame tranche d\u2019\u00e2ge. (1,2,3<\/sup>) Ils signalent chaque ann\u00e9e 100 \u00e0 300 d\u00e9c\u00e8s d\u2019enfants de moins de 5 ans dus au VRS.4<\/sup>
    Les nouveau-n\u00e9s et les nourrissons de moins de six mois et ceux n\u00e9s pr\u00e9matur\u00e9ment (avant 35 semaines de gestation) courent le plus grand risque de d\u00e9velopper une infection suffisamment grave pour n\u00e9cessiter une hospitalisation. Ces infections par le VRS n\u00e9cessitent g\u00e9n\u00e9ralement une surveillance \u00e9troite de la respiration du jeune enfant. Le nourrisson ou l'enfant hospitalis\u00e9 peut avoir besoin d'une assistance respiratoire, de m\u00e9dicaments et d'un apport liquidien intraveineux (IV) pendant la pire partie de la maladie.<\/p>\n

    Beyfortus a \u00e9t\u00e9 cr\u00e9\u00e9 pour pr\u00e9venir une infection grave par le VRS chez les nourrissons au cours de leur premi\u00e8re saison du VRS, lorsqu'ils sont les plus \u00e0 risque de complications du virus. Selon un communiqu\u00e9 de presse du fabricant Sanofi : \u00ab L'administration unique de Beyfortus a \u00e9t\u00e9 d\u00e9velopp\u00e9e pour correspondre au d\u00e9but de la saison du VRS pour les b\u00e9b\u00e9s n\u00e9s avant la saison ou \u00e0 la naissance pour ceux n\u00e9s pendant la saison du VRS. Dans le cadre d'essais cliniques, Beyfortus a contribu\u00e9 \u00e0 pr\u00e9venir la maladie des voies respiratoires inf\u00e9rieures due au VRS n\u00e9cessitant des soins m\u00e9dicaux dans toutes les populations de nourrissons \u00e9tudi\u00e9es, y compris ceux n\u00e9s \u00e0 terme, peu pr\u00e9matur\u00e9s ou pr\u00e9matur\u00e9s en bonne sant\u00e9, ou pr\u00e9sentant des probl\u00e8mes de sant\u00e9 sp\u00e9cifiques qui les rendent vuln\u00e9rables \u00e0 une maladie grave \u00e0 VRS. Les maladies \u00e0 VRS n\u00e9cessitant des soins m\u00e9dicaux comprenaient le cabinet d\u2019un m\u00e9decin, les soins d\u2019urgence, les visites aux urgences et les hospitalisations.5<\/sup><\/p>\n

    Le Comit\u00e9 consultatif sur les pratiques d'immunisation (ACIP) et l'American Academy of Pediatrics (AAP) recommandent d\u00e9sormais Beyfortus \u00e0 tous les nourrissons de moins de 8 mois pendant ou entrant dans leur premi\u00e8re saison de VRS. Le gouvernement f\u00e9d\u00e9ral est intervenu pour couvrir le co\u00fbt des m\u00e9dicaments en milieu extra-hospitalier pour les enfants inscrits au programme de vaccins pour enfants (VFC). Le programme VFC aide g\u00e9n\u00e9ralement \u00e0 fournir des vaccins aux enfants dont les tuteurs n'auraient peut-\u00eatre pas pu se les procurer autrement. Les assureurs priv\u00e9s n\u2019ont pas d\u00e9termin\u00e9 quelle part du pr\u00e9tendu co\u00fbt du $415 ils envisagent de couvrir.<\/p>\n

    Cela laisse aux h\u00f4pitaux et aux cabinets m\u00e9dicaux priv\u00e9s le soin de d\u00e9terminer la meilleure fa\u00e7on de d\u00e9ployer ce m\u00e9dicament, ce qui suscite des inqui\u00e9tudes quant \u00e0 l\u2019acc\u00e8s et \u00e0 l\u2019\u00e9quit\u00e9. Les prestataires proposant le Beyfortus couvert par VFC dans leurs cabinets doivent \u00e9galement le proposer aux patients b\u00e9n\u00e9ficiant d'une assurance priv\u00e9e. Cela signifie payer entre des milliers et un million de dollars pour offrir ce m\u00e9dicament. Un co\u00fbt qui pourrait ne pas \u00eatre r\u00e9cup\u00e9r\u00e9 par la plupart des h\u00f4pitaux ou cabinets. Les d\u00e9cisions seront alors probablement prises au niveau local d'offrir ou non Beyfortus \u00e0 un enfant, ce qui rendra la distribution au mieux variable et au pire exclure ceux des zones les moins riches.<\/p>\n

    Beyfortus r\u00e9duit le risque d'infection par le VRS n\u00e9cessitant des soins m\u00e9dicaux d'environ 70-75% par rapport au placebo.6<\/sup> Malgr\u00e9 ces donn\u00e9es, l\u2019analyse co\u00fbts-avantages doit \u00eatre prise au s\u00e9rieux. Pour tout parent ayant un enfant malade ou hospitalis\u00e9 atteint du VRS, il n\u2019y a aucun co\u00fbt trop \u00e9lev\u00e9 pour pr\u00e9venir cette maladie. Les h\u00f4pitaux du pays sont confront\u00e9s \u00e0 de graves contraintes financi\u00e8res, avec un acc\u00e8s aux soins consid\u00e9rablement restreint, en particulier dans les zones rurales. Plus t\u00f4t cette ann\u00e9e, un rapport du Center for Healthcare Quality and Payment Reform a soulign\u00e9 le risque de voir de nouveaux h\u00f4pitaux fermer dans un avenir proche : \u00ab Plus de 100 h\u00f4pitaux ruraux ont ferm\u00e9 leurs portes au cours de la derni\u00e8re d\u00e9cennie, et plus de 600 h\u00f4pitaux ruraux suppl\u00e9mentaires \u2014 plus de 30% de tous les h\u00f4pitaux ruraux du pays risquent de fermer dans un avenir proche. Les h\u00f4pitaux ruraux risquent de fermer parce qu\u2019ils perdent de l\u2019argent en fournissant des services aux patients. Dans le pass\u00e9, de nombreux h\u00f4pitaux ont re\u00e7u des subventions, des recettes fiscales locales ou des subventions d\u2019autres entreprises pour compenser ces pertes, mais rien ne garantit que ces fonds continueront d\u2019\u00eatre disponibles ou seront suffisants pour couvrir les co\u00fbts plus \u00e9lev\u00e9s auxquels les h\u00f4pitaux sont confront\u00e9s. Des millions de personnes pourraient \u00eatre directement touch\u00e9es si ces h\u00f4pitaux fermaient. \u00bb7<\/sup><\/p>\n

    Alors que les assureurs, le gouvernement et les prestataires m\u00e9dicaux prennent en compte ces facteurs complexes, la saison du VRS approche \u00e0 grands pas. Il est fort probable que la mise en \u0153uvre compl\u00e8te et la disponibilit\u00e9 de Beyfortus ne seront pas appr\u00e9ci\u00e9es au cours de la prochaine saison du RSV.<\/p>\n

    Ouvrages cit\u00e9s:<\/p>\n

      \n
    1. Hall CB, Weinberg GA, Iwane MK et al. Le fardeau de l\u2019infection par le virus respiratoire syncytial chez les jeunes enfants. Nouvel Anglais J Med. 2009;360(6):588-98.<\/a><\/li>\n
    2. Rha B, Curns AT, Lively JY et al. Hospitalisations associ\u00e9es au virus respiratoire syncytial chez les jeunes enfants\u00a0: 2015-2016. P\u00e9diatrie. 2020;146(1):e20193611.<\/a><\/li>\n
    3. McLaughlin JM, Khan F, Schmitt HJ et coll. Taux d'hospitalisation associ\u00e9s au virus respiratoire syncytial chez les nourrissons am\u00e9ricains\u00a0: une revue syst\u00e9matique et une m\u00e9ta-analyse. JID. 2022;225(6):1100-1111.<\/a><\/li>\n
    4. Hansen CL, Chaves SS, Demont C, Viboud C. Mortalit\u00e9 associ\u00e9e \u00e0 la grippe et au virus respiratoire syncytial aux \u00c9tats-Unis, 1999-2018.R\u00e9seau JAMA ouvert. 1er f\u00e9vrier 2022;5(2):e220527.<\/a><\/li>\n
    5. https:\/\/www.news.sanofi.us\/2023-07-17-FDA-approves-Beyfortus-TM-nirsevimab-alip-to-protect-infants-against-RSV-disease<\/a><\/li>\n
    6. https:\/\/www.beyfortus.com\/hcp\/efficacy-and-safety#Efficacy<\/a><\/li>\n
    7. Sauver les h\u00f4pitaux ruraux \u2013 La crise des soins de sant\u00e9 en milieu rural (chqpr.org)<\/a><\/li>\n<\/ol>","protected":false},"author":2,"featured_media":8752,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"fifu_image_url":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/rsv-prevention-in-newborns.png","fifu_image_alt":"","footnotes":""},"categories":[27],"tags":[],"class_list":["post-8751","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"yoast_head":"\nRSV Prevention in Newborns - Urban Care Clinic<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/urbancare.clinic\/fr\/prevention-du-vrs-chez-les-nouveau-nes\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RSV Prevention in Newborns - Urban Care Clinic\" \/>\n<meta property=\"og:description\" content=\"Beyfortus (generic name: Nirsevimab) was approved by the United States Food and Drug Administration (FDA) on July 17, 2023. Beyfortus is a long-acting monoclonal antibody designed to protect newborns and infants from medically attended respiratory syncytial virus (RSV) infection. For the purposes of the Beyfortus drug trials, "medically attended" refers to any RSV infection requiring a doctor's visit in the office, urgent care, or hospital.RSV is the most common cause of lower lung infections in children less than one year of age. These types of lung infections include bronchiolitis and\/or pneumonia. Bronchiolitis often begins with a runny nose and cough, but can worsen to include a faster breathing rate, wheezing, crackles, and needing to work harder to breathe. Infants are at risk for developing apnea, which is defined as a temporary pause in breathing or the absence of breathing for greater than 20 seconds.According to the Centers for Disease Control and Prevention (CDC), RSV causes approximately 2.1 million non-hospital doctor's office visits each year in children less than 5 years old1 as well as 58,000-80,000 hospitalizations each year in that same age group. (1,2,3) They report 100-300 deaths in children younger than 5 years due to RSV annually.4Newborns and infants less than six months of age and those born prematurely (before 35 weeks gestation) are at the highest risk for having an infection severe enough to require hospitalization. These RSV infections usually require closely monitoring the young child's breathing. The hospitalized infant or child may need breathing support, medications, and intravenous (IV) fluid support during the worst portion of the illness.Beyfortus was created to prevent severe RSV infection in infants during their first RSV season, when they are at the highest risk for complications from the virus. According to a press release from the manufacturer, Sanofi: "The single administration of Beyfortus was developed to correspond with the beginning of the RSV season for babies born prior to the season or at birth for those born during the RSV season. In clinical trials, Beyfortus helped prevent RSV LRTD [lower respiratory tract disease] requiring medical care in all infant populations studied, including those born healthy at term, late preterm or preterm, or with specific health conditions that make them vulnerable to severe RSV disease. RSV disease requiring medical care included physician office, urgent care, emergency room visits, and hospitalizations."5The Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) are now recommending Beyfortus to all infants less than 8 months of age during or entering their first RSV season. The federal government has stepped in to cover the medication cost in out-of-hospital settings for children enrolled in the Vaccine for Children (VFC) Program. The VFC Program generally helps provide vaccines to children whose caregivers may not have been otherwise able to afford them. Private insurers have not determined how much of the purported $415 cost they plan to cover.This leaves hospitals and private medical practices to determine how best to deploy this medication, which leads to concerns about access and equity. Providers offering the VFC-covered Beyfortus in their offices must also offer it to patients with private insurance. This means paying out anywhere from thousands to a million plus dollars to offer this medication. A cost that may not be recuperated by most hospitals or practices. The decisions will then likely be made on a local level whether or not to offer Beyfortus to any child, which will render distribution to be variable at best and to exclude those in less affluent areas at worst.Beyfortus reduces the risk of RSV infection that requires medical attention by approximately 70-75% relative to placebo.6 Despite this data, the cost-benefit analysis needs to be taken seriously. For any parent with a sick or hospitalized child with RSV, there is no cost too high to prevent that illness. Hospitals nationwide are facing serious financial constraints, with access to care significantly strained, especially in rural areas. Earlier this year, a report from the Center for Healthcare Quality and Payment Reform highlighted the risk for additional hospitals to close in the near future: "More than 100 rural hospitals have closed over the past decade, and more than 600 additional rural hospitals \u2014 over 30% of all rural hospitals in the country \u2014 are at risk of closing in the near future. Rural hospitals are at risk of closure because they lose money delivering services to patients. In the past, many hospitals have received grants, local tax revenues, or subsidies from other businesses that offset these losses, but there is no guarantee that these funds will continue to be available or sufficient to cover the higher costs hospitals are experiencing. Millions of people could be directly harmed if these hospitals close."7While the insurers, government, and medical providers consider these complex factors, RSV season is rapidly approaching. It is quite likely that the full implementation and availability of Beyfortus will not be appreciated during the upcoming RSV season.Works Cited:Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. New Engl J Med. 2009;360(6):588\u201398.Rha B, Curns AT, Lively JY, et al. Respiratory Syncytial Virus\u2013Associated Hospitalizations Among Young Children: 2015\u20132016.Pediatrics. 2020;146(1):e20193611.McLaughlin JM, Khan F, Schmitt H-J, et al. Respiratory Syncytial Virus\u2013Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis. JID. 2022;225(6):1100-1111.Hansen CL, Chaves SS, Demont C, Viboud C. Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018.JAMA Network Open. 2022 Feb 1;5(2):e220527.https:\/\/www.news.sanofi.us\/2023-07-17-FDA-approves-Beyfortus-TM-nirsevimab-alip-to-protect-infants-against-RSV-diseasehttps:\/\/www.beyfortus.com\/hcp\/efficacy-and-safety#EfficacySaving Rural Hospitals - The Crisis in Rural Health Care (chqpr.org)\" \/>\n<meta property=\"og:url\" content=\"https:\/\/urbancare.clinic\/fr\/prevention-du-vrs-chez-les-nouveau-nes\/\" \/>\n<meta property=\"og:site_name\" content=\"Urban Care Clinic\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/urbancarezanzibar\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-11T15:15:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/rsv-prevention-in-newborns.png\" \/>\n<meta name=\"author\" content=\"Urban Care Clinic\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/rsv-prevention-in-newborns.png\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Urban Care Clinic\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/\"},\"author\":{\"name\":\"Urban Care Clinic\",\"@id\":\"https:\/\/urbancare.clinic\/#\/schema\/person\/f286c4d84be896d302aceda3ed7e789c\"},\"headline\":\"RSV Prevention in Newborns\",\"datePublished\":\"2023-10-11T15:15:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/\"},\"wordCount\":942,\"publisher\":{\"@id\":\"https:\/\/urbancare.clinic\/#organization\"},\"image\":{\"@id\":\"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/rsv-prevention-in-newborns.png\",\"articleSection\":[\"Medical Daily\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/\",\"url\":\"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/\",\"name\":\"RSV Prevention in Newborns - Urban Care Clinic\",\"isPartOf\":{\"@id\":\"https:\/\/urbancare.clinic\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/rsv-prevention-in-newborns.png\",\"datePublished\":\"2023-10-11T15:15:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/#primaryimage\",\"url\":\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/rsv-prevention-in-newborns.png\",\"contentUrl\":\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/rsv-prevention-in-newborns.png\",\"caption\":\"RSV Prevention in Newborns\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/urbancare.clinic\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RSV Prevention in Newborns\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/urbancare.clinic\/#website\",\"url\":\"https:\/\/urbancare.clinic\/\",\"name\":\"Urban Care Clinic\",\"description\":\"Your Medical Healthcare Clinic in Zanzibar\",\"publisher\":{\"@id\":\"https:\/\/urbancare.clinic\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/urbancare.clinic\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/urbancare.clinic\/#organization\",\"name\":\"Urban Care Clinic Zanzibar\",\"alternateName\":\"Urban Care Clinic\",\"url\":\"https:\/\/urbancare.clinic\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/urbancare.clinic\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2022\/07\/Urban-Care-Clinic-Logo-Trans-512x512-1.png\",\"contentUrl\":\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2022\/07\/Urban-Care-Clinic-Logo-Trans-512x512-1.png\",\"width\":500,\"height\":500,\"caption\":\"Urban Care Clinic Zanzibar\"},\"image\":{\"@id\":\"https:\/\/urbancare.clinic\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/urbancarezanzibar\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/urbancare.clinic\/#\/schema\/person\/f286c4d84be896d302aceda3ed7e789c\",\"name\":\"Urban Care Clinic\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/urbancare.clinic\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/8f8b5f9c42679ce61ae24fd31561a4574502595c4b3428a4fdf92d929bf09352?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/8f8b5f9c42679ce61ae24fd31561a4574502595c4b3428a4fdf92d929bf09352?s=96&d=mm&r=g\",\"caption\":\"Urban Care Clinic\"},\"url\":\"https:\/\/urbancare.clinic\/fr\/author\/urban-care-clinic\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pr\u00e9vention du VRS chez les nouveau-n\u00e9s - Urban Care Clinic","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/urbancare.clinic\/fr\/prevention-du-vrs-chez-les-nouveau-nes\/","og_locale":"fr_FR","og_type":"article","og_title":"RSV Prevention in Newborns - Urban Care Clinic","og_description":"Beyfortus (generic name: Nirsevimab) was approved by the United States Food and Drug Administration (FDA) on July 17, 2023. Beyfortus is a long-acting monoclonal antibody designed to protect newborns and infants from medically attended respiratory syncytial virus (RSV) infection. For the purposes of the Beyfortus drug trials, \"medically attended\" refers to any RSV infection requiring a doctor's visit in the office, urgent care, or hospital.RSV is the most common cause of lower lung infections in children less than one year of age. These types of lung infections include bronchiolitis and\/or pneumonia. Bronchiolitis often begins with a runny nose and cough, but can worsen to include a faster breathing rate, wheezing, crackles, and needing to work harder to breathe. Infants are at risk for developing apnea, which is defined as a temporary pause in breathing or the absence of breathing for greater than 20 seconds.According to the Centers for Disease Control and Prevention (CDC), RSV causes approximately 2.1 million non-hospital doctor's office visits each year in children less than 5 years old1 as well as 58,000-80,000 hospitalizations each year in that same age group. (1,2,3) They report 100-300 deaths in children younger than 5 years due to RSV annually.4Newborns and infants less than six months of age and those born prematurely (before 35 weeks gestation) are at the highest risk for having an infection severe enough to require hospitalization. These RSV infections usually require closely monitoring the young child's breathing. The hospitalized infant or child may need breathing support, medications, and intravenous (IV) fluid support during the worst portion of the illness.Beyfortus was created to prevent severe RSV infection in infants during their first RSV season, when they are at the highest risk for complications from the virus. According to a press release from the manufacturer, Sanofi: \"The single administration of Beyfortus was developed to correspond with the beginning of the RSV season for babies born prior to the season or at birth for those born during the RSV season. In clinical trials, Beyfortus helped prevent RSV LRTD [lower respiratory tract disease] requiring medical care in all infant populations studied, including those born healthy at term, late preterm or preterm, or with specific health conditions that make them vulnerable to severe RSV disease. RSV disease requiring medical care included physician office, urgent care, emergency room visits, and hospitalizations.\"5The Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) are now recommending Beyfortus to all infants less than 8 months of age during or entering their first RSV season. The federal government has stepped in to cover the medication cost in out-of-hospital settings for children enrolled in the Vaccine for Children (VFC) Program. The VFC Program generally helps provide vaccines to children whose caregivers may not have been otherwise able to afford them. Private insurers have not determined how much of the purported $415 cost they plan to cover.This leaves hospitals and private medical practices to determine how best to deploy this medication, which leads to concerns about access and equity. Providers offering the VFC-covered Beyfortus in their offices must also offer it to patients with private insurance. This means paying out anywhere from thousands to a million plus dollars to offer this medication. A cost that may not be recuperated by most hospitals or practices. The decisions will then likely be made on a local level whether or not to offer Beyfortus to any child, which will render distribution to be variable at best and to exclude those in less affluent areas at worst.Beyfortus reduces the risk of RSV infection that requires medical attention by approximately 70-75% relative to placebo.6 Despite this data, the cost-benefit analysis needs to be taken seriously. For any parent with a sick or hospitalized child with RSV, there is no cost too high to prevent that illness. Hospitals nationwide are facing serious financial constraints, with access to care significantly strained, especially in rural areas. Earlier this year, a report from the Center for Healthcare Quality and Payment Reform highlighted the risk for additional hospitals to close in the near future: \"More than 100 rural hospitals have closed over the past decade, and more than 600 additional rural hospitals \u2014 over 30% of all rural hospitals in the country \u2014 are at risk of closing in the near future. Rural hospitals are at risk of closure because they lose money delivering services to patients. In the past, many hospitals have received grants, local tax revenues, or subsidies from other businesses that offset these losses, but there is no guarantee that these funds will continue to be available or sufficient to cover the higher costs hospitals are experiencing. Millions of people could be directly harmed if these hospitals close.\"7While the insurers, government, and medical providers consider these complex factors, RSV season is rapidly approaching. It is quite likely that the full implementation and availability of Beyfortus will not be appreciated during the upcoming RSV season.Works Cited:Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. New Engl J Med. 2009;360(6):588\u201398.Rha B, Curns AT, Lively JY, et al. Respiratory Syncytial Virus\u2013Associated Hospitalizations Among Young Children: 2015\u20132016.Pediatrics. 2020;146(1):e20193611.McLaughlin JM, Khan F, Schmitt H-J, et al. Respiratory Syncytial Virus\u2013Associated Hospitalization Rates among US Infants: A Systematic Review and Meta-Analysis. JID. 2022;225(6):1100-1111.Hansen CL, Chaves SS, Demont C, Viboud C. Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018.JAMA Network Open. 2022 Feb 1;5(2):e220527.https:\/\/www.news.sanofi.us\/2023-07-17-FDA-approves-Beyfortus-TM-nirsevimab-alip-to-protect-infants-against-RSV-diseasehttps:\/\/www.beyfortus.com\/hcp\/efficacy-and-safety#EfficacySaving Rural Hospitals - The Crisis in Rural Health Care (chqpr.org)","og_url":"https:\/\/urbancare.clinic\/fr\/prevention-du-vrs-chez-les-nouveau-nes\/","og_site_name":"Urban Care Clinic","article_publisher":"https:\/\/www.facebook.com\/urbancarezanzibar","article_published_time":"2023-10-11T15:15:06+00:00","og_image":[{"url":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/rsv-prevention-in-newborns.png","type":"","width":"","height":""}],"author":"Urban Care Clinic","twitter_card":"summary_large_image","twitter_image":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/rsv-prevention-in-newborns.png","twitter_misc":{"\u00c9crit par":"Urban Care Clinic","Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/#article","isPartOf":{"@id":"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/"},"author":{"name":"Urban Care Clinic","@id":"https:\/\/urbancare.clinic\/#\/schema\/person\/f286c4d84be896d302aceda3ed7e789c"},"headline":"RSV Prevention in Newborns","datePublished":"2023-10-11T15:15:06+00:00","mainEntityOfPage":{"@id":"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/"},"wordCount":942,"publisher":{"@id":"https:\/\/urbancare.clinic\/#organization"},"image":{"@id":"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/#primaryimage"},"thumbnailUrl":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/rsv-prevention-in-newborns.png","articleSection":["Medical Daily"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/","url":"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/","name":"Pr\u00e9vention du VRS chez les nouveau-n\u00e9s - Urban Care Clinic","isPartOf":{"@id":"https:\/\/urbancare.clinic\/#website"},"primaryImageOfPage":{"@id":"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/#primaryimage"},"image":{"@id":"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/#primaryimage"},"thumbnailUrl":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/rsv-prevention-in-newborns.png","datePublished":"2023-10-11T15:15:06+00:00","breadcrumb":{"@id":"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/#primaryimage","url":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/rsv-prevention-in-newborns.png","contentUrl":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/rsv-prevention-in-newborns.png","caption":"RSV Prevention in Newborns"},{"@type":"BreadcrumbList","@id":"https:\/\/urbancare.clinic\/rsv-prevention-in-newborns\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/urbancare.clinic\/"},{"@type":"ListItem","position":2,"name":"RSV Prevention in Newborns"}]},{"@type":"WebSite","@id":"https:\/\/urbancare.clinic\/#website","url":"https:\/\/urbancare.clinic\/","name":"Clinique de soins urbains","description":"Votre clinique de soins m\u00e9dicaux \u00e0 Zanzibar","publisher":{"@id":"https:\/\/urbancare.clinic\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/urbancare.clinic\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/urbancare.clinic\/#organization","name":"Clinique de soins urbains Zanzibar","alternateName":"Urban Care Clinic","url":"https:\/\/urbancare.clinic\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/urbancare.clinic\/#\/schema\/logo\/image\/","url":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2022\/07\/Urban-Care-Clinic-Logo-Trans-512x512-1.png","contentUrl":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2022\/07\/Urban-Care-Clinic-Logo-Trans-512x512-1.png","width":500,"height":500,"caption":"Urban Care Clinic Zanzibar"},"image":{"@id":"https:\/\/urbancare.clinic\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/urbancarezanzibar"]},{"@type":"Person","@id":"https:\/\/urbancare.clinic\/#\/schema\/person\/f286c4d84be896d302aceda3ed7e789c","name":"Clinique de soins urbains","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/urbancare.clinic\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/8f8b5f9c42679ce61ae24fd31561a4574502595c4b3428a4fdf92d929bf09352?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8f8b5f9c42679ce61ae24fd31561a4574502595c4b3428a4fdf92d929bf09352?s=96&d=mm&r=g","caption":"Urban Care Clinic"},"url":"https:\/\/urbancare.clinic\/fr\/author\/urban-care-clinic\/"}]}},"_links":{"self":[{"href":"https:\/\/urbancare.clinic\/fr\/wp-json\/wp\/v2\/posts\/8751","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/urbancare.clinic\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/urbancare.clinic\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/urbancare.clinic\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/urbancare.clinic\/fr\/wp-json\/wp\/v2\/comments?post=8751"}],"version-history":[{"count":0,"href":"https:\/\/urbancare.clinic\/fr\/wp-json\/wp\/v2\/posts\/8751\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/urbancare.clinic\/fr\/wp-json\/wp\/v2\/media\/8752"}],"wp:attachment":[{"href":"https:\/\/urbancare.clinic\/fr\/wp-json\/wp\/v2\/media?parent=8751"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/urbancare.clinic\/fr\/wp-json\/wp\/v2\/categories?post=8751"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/urbancare.clinic\/fr\/wp-json\/wp\/v2\/tags?post=8751"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}